During the chronic phase of CML, after single-cell trajectory reconstitution on prognosis phenotype, CD63 regulation highlighted a trajectory cluster implicating HSPB1, PIM2, ANXA5, LAMTOR1, CFL1, CD52, RAD52, MEIS1, and PDIA3 molecules characterizing hematopoietic malignancies like myelodysplasia, acute myeloid leukemia, and acute lymphoid leukemia. Here, PIM2 is linked to acute lymphoblastic leukemia.